Last reviewed · How we verify
NCT00297895
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
NA trial testing Completion Lymphadenectomy in Melanoma in 1,939 participants. Completed in 30 September 2019.
30 September 2019
Quick facts
| Lead sponsor | Saint John's Cancer Institute |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1,939 |
| Start date | 30 September 2004 |
| Primary completion | 30 September 2019 |
| Estimated completion | 30 September 2019 |
| Sites | 63 locations across Italy, Finland, Netherlands, Sweden, United Kingdom, Germany, Israel, Canada |
Drugs / interventions tested
- Completion Lymphadenectomy
- Monitoring with nodal ultrasound
Conditions studied
- Melanoma — all drugs for Melanoma →
Sponsor
Saint John's Cancer Institute
Who can join
Adults 18 to 75, any sex, with Melanoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Subjects must be diagnosed with melanoma. All subjects receive sentinel lymphadenectomy. If the subject is sentinel node positive and meets study requirements, the subject is randomized to receive either (1) completion lymphadenectomy (2) observation with nodal ultrasound. Subjects are then followed for 10 years.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.
Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, et al · · 2017 · cited 911× · PMID 28591523 · DOI 10.1056/nejmoa1613210 -
Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial.
Multicenter Selective Lymphadenectomy Trials Study Group, Crystal JS, Thompson JF, Hyngstrom J, et al · · 2022 · cited 44× · PMID 35921122 · DOI 10.1001/jamasurg.2022.2055 -
Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy.
Salama AK, de Rosa N, Scheri RP, Pruitt SK, et al · · 2013 · cited 34× · PMID 23516415 · DOI 10.1371/journal.pone.0057665 -
Malignant Melanoma.
Perera E, Gnaneswaran N, Jennens R, Sinclair R. · · 2013 · cited 32× · PMID 27429256 · DOI 10.3390/healthcare2010001 -
Lymph nodes: at the intersection of cancer treatment and progression.
Reticker-Flynn NE, Engleman EG. · · 2023 · cited 31× · PMID 37149414 · DOI 10.1016/j.tcb.2023.04.001 -
The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma.
Jones MS, Jones PC, Stern SL, Elashoff D, et al · · 2017 · cited 26× · PMID 28224364 · DOI 10.1245/s10434-017-5775-9 -
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.
Slingluff CL, Lewis KD, Andtbacka R, Hyngstrom J, et al · · 2021 · cited 16× · PMID 34599031 · DOI 10.1136/jitc-2021-003272 -
Case report: Patient specific combination of surgery and immunotherapy in advanced squamous cell carcinoma of the head and neck - a case series and review of literature.
Olmos M, Lutz R, Büntemeyer TO, Glajzer J, et al · · 2022 · cited 10× · PMID 36389668 · DOI 10.3389/fimmu.2022.970823
Verify or expand the search:
- PubMed search for NCT00297895
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Melanoma
Currently open trials in the same condition.
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07225036 — Promoting Immunotherapy Efficacy With Low-Dose Liver RT · NA · recruiting
- NCT07379138 — Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improve · NA · recruiting
Other Saint John's Cancer Institute trials
Trials by the same sponsor.
- NCT05289466 — Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With P · NA · terminated
- NCT03955042 — Pemetrexed for the Treatment of Chordoma · Phase 1 · completed
- NCT04082611 — The PREVENTION Trial: Precision Recommendations to Optimize Neurocognition · NA · completed
- NCT04603209 — Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer · recruiting
- NCT03069287 — Integrating Family Caregiver Support Into Cancer Clinical Trials · NA · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00297895 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Saint John's Cancer Institute
- Last refreshed: 13 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00297895.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing